Takeda, Merck & Co, Ipsen and Merck Group all scored exits as the immuno-oncology drug developer floated at the bottom of its IPO range.

Xilio Therapeutics, a US-based cancer immunotherapy developer backed by pharmaceutical firms Takeda, Merck & Co, Ipsen and Merck Group, floated on Friday in an initial public offering sized at almost $118m.

The company issued approximately 7.35 million shares on the Nasdaq Global Market priced at the foot of the offering’s $16 to $18 range. They opened at $15.00 on Friday and closed at the IPO price of $16.00, giving it a market capitalisation of nearly $429m.

Joint book-running managers Morgan…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.